Non-neurotoxic plasminogen activating factors for treating...

Details Non-neurotoxic plasminogen activating factors for treating... Non-neurotoxic plasminogen activating factors for treating...

2008-06-27

2011-12-06

Rao, Manjunath (Department: 1656)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C435S226000

Reexamination Certificate

active

08071091

ABSTRACT:
The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. ofDesmodus rotundus(DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans.

REFERENCES:
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 5094953 (1992-03-01), Anderson et al.
patent: 5223256 (1993-06-01), Stern et al.
patent: 5244806 (1993-09-01), Bang et al.
patent: 5314818 (1994-05-01), Anderson et al.
patent: 5326700 (1994-07-01), Berg et al.
patent: 5500411 (1996-03-01), Martin et al.
patent: 5510330 (1996-04-01), Martin et al.
patent: 5595736 (1997-01-01), Berg et al.
patent: 5648250 (1997-07-01), Niwa et al.
patent: 5676947 (1997-10-01), Martin et al.
patent: 5714145 (1998-02-01), Anderson et al.
patent: 5731186 (1998-03-01), McCaman et al.
patent: 5741771 (1998-04-01), Dawson et al.
patent: 5786187 (1998-07-01), Strickland et al.
patent: 5827832 (1998-10-01), Sandage et al.
patent: 5830849 (1998-11-01), Dixon et al.
patent: 5876971 (1999-03-01), Noeske-Jungblut et al.
patent: 5891664 (1999-04-01), Danø et al.
patent: 5945432 (1999-08-01), Bednar et al.
patent: 6008019 (1999-12-01), Baldus et al.
patent: 6235278 (2001-05-01), Miller
patent: 6235279 (2001-05-01), Martin et al.
patent: 6248712 (2001-06-01), Danø et al.
patent: 2002/0081294 (2002-06-01), Bednar et al.
patent: 2002/0098179 (2002-07-01), Brearley et al.
patent: 2005/0048027 (2005-03-01), Söhngen et al.
patent: 2006/0135425 (2006-06-01), Sohngen et al.
patent: 2006/0142195 (2006-06-01), Medcalf et al.
patent: 2008/0057050 (2008-03-01), Sohngen et al.
patent: 2008/0213244 (2008-09-01), Sohngen
patent: 2009/0004176 (2009-01-01), Medcalf et al.
patent: 2009/0263373 (2009-10-01), Sohngen et al.
patent: 2010/0272704 (2010-10-01), Sohngen et al.
patent: 5 524 573 (2004-11-01), None
patent: 39 04 580 (1990-08-01), None
patent: 39 17 949 (1991-01-01), None
patent: 41 23 845 (1993-01-01), None
patent: 689 16 532 (1995-01-01), None
patent: 692 15 537 (1997-04-01), None
patent: 692 15 537 (1997-04-01), None
patent: 0 242 836 (1987-10-01), None
patent: 0 273 774 (1988-07-01), None
patent: 0 352 119 (1990-01-01), None
patent: 0 352 710 (1990-01-01), None
patent: 0 383 417 (1990-08-01), None
patent: 0 386 240 (1990-09-01), None
patent: 0 618 973 (1994-10-01), None
patent: 0 093 619 (1996-09-01), None
patent: 1 308 166 (2003-05-01), None
patent: 6506459 (1994-07-01), None
patent: WO 89/09266 (1989-10-01), None
patent: WO 91/05048 (1991-04-01), None
patent: WO 93/12238 (1993-06-01), None
patent: WO 96/01312 (1996-01-01), None
patent: WO 97/29188 (1998-08-01), None
patent: WO 01/51613 (2001-07-01), None
patent: WO 01/51614 (2001-07-01), None
patent: WO 03/037363 (2003-05-01), None
patent: WO 03/037363 (2003-05-01), None
patent: WO 2004/096267 (2004-11-01), None
patent: WO 2004/096268 (2004-11-01), None
patent: WO 2004/098635 (2004-11-01), None
patent: WO-2005/018564 (2005-03-01), None
patent: WO 2005/026341 (2005-03-01), None
Mellott, M. J., et al., 1992, “Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion withour concomitatant systemic plasminogen activation in a canine model of arterial thrombosis”, Arteriosclerosis and Thrombosis, vol. 12, No. 2 pp. 212-221.
Abstract of DE 39 04 580, published Aug. 16, 1990.
Abstract of EP 1 308 166, published May 7, 2003.
Abstract of WO 04/096267, published Nov. 11, 2004.
Abstract of WO 04/098635, published Nov. 18, 2004.
Abstract of EP 0 242 836, published Oct. 28, 1987.
Adams, H. P., et al., “Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke, a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association,” Circulation, 94(5):1167-1174 (1996).
Adams, H. P., et al., “Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American stroke association,” Stroke, 34:1056-1083 (2003).
Albers, G. W., et al., “Antithrombotic and thrombolytic therapy for ischemic stroke: American college of chest physicians evidence-based clinical practice guidelines (8thedition),” Chest, 133:630S-669S (2008).
Albers, G. W., et al., “Desmoteplase 3-9 hours after acute ischemic stroke: an update on the DIAS clinical trial program,” Poster at the International Stroke Conference, Feb. 24, 2010.
Alkawi, A., et al., “Advances in thrombolytics and mechanical devices for treatment of acute ischemic stroke,” Neurological Research, 27(1):542-549 (2005).
Asplund, K., et al., “How do stroke units improve patients outcomes? a collaborative systematic review of the randomized trials,” Stroke, 28(11):2139-2144 (1997).
Atalaya, J. L., et al., “Neurotransmitters and receptors,” Journal of Cerebral Blood Flow & Metabolism, 25:S578 (2005).
Bath, Philip, “Alteplase not yet proven for acute ischaemic stroke,” The Lancet, 352:1238-1239 (1998).
Bhana, N., et al., “Lanoteplase,” Biodrugs, 13(3):217-224 (2000).
Bondaryk, et al., “Microheterogeneity, standardization and characterization in glycoprotein drugs,” Curr. Drug Discov., 4:31-32 (2004).
Broderick, J.P. et al., “Treatment of acute ischemic stroke: part I: recanalization strategies,” Circulation, 106:1563-1569 (2002).
Brott, T. et al., “Treatment of acute ischemic stroke,” The New Engl. J. Med., 343(10):710-722 (2000).
Clark, W. M., et al, “The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A 0276g) : results of a double-blind, placebo-controlled, multicenter study,” Stroke, 31:811-816 (2002).
CoIlen, D., “Fibrin-selective thrombolytic therapy for acute myocardial infarction,” Circulation, 93:857-865 (1996).
Colman, A., et al., “Post-translational modification of exogenous proteins inXenopus laevisoocytes,” Biochemical Society Transactions, 12:932-937 (1984).
Degen, S.J.F., et al., “The human tissue plasminogen activator gene,” The Journal of Biological Chemistry, 261(15):6972-6985 (1986).
del Zoppo, G.J., et al., “Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke,” Ann Neurol, 32(1):78-86 (1992)—ABSTRACT.
DiMasi, J. A., et al., “The price of innovation: new estimates of drug development costs,” Journal of Health Economics, 22:151-185 (2003).
Donnan, G. A., et al., “Stroke drug development usually, but not always, animal models,” Stroke, 36:2326 (2005).
Epple, G. et al., “Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2,” Journal of Thrombosis and Haemostasis, 2:962-968 (2004).
Fisher, M., et al., “Recommendations for standards regarding preclinical neuroprotective and restorative drug development,” Stroke, 30:2752-2758 (1999).
Fisher, M., “Use of animal models has not contributed to development of acute stroke therapies con,” Stroke, 36:2324-2325 (2005).
Fisher, M., “Enhancing the development and approval of acute stroke therapies, stroke therapy academic industry roundtable,” Stroke, 36:1808-1813 (2005).
Fisher, M., et al., “Emerging therapies for acute ischemic stroke new therapies on trial,” Stroke, 34:359-361 (2003).
Fisher, M., “The ischemic penumbra: a new opportunity for neuroprotection,” Cerebrovasc Dis, 21(2):64-70 (2006).
Furlan, A., et al., “Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset,” Stroke, 37:1227-1231 (2006).
Furlan, A., et al., “Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial,” JAMA, 282(21):2003-2011 (1999).
“GISSI-2: a factorial randomized trial of alteplase

Affiliated with

Also associated with

Rating

Non-neurotoxic plasminogen activating factors for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-neurotoxic plasminogen activating factors for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-neurotoxic plasminogen activating factors for treating... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4259962